MannKind/$MNKD
1D1W1MYTD1Y5YMAX
Capital at risk
About MannKind
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
- Ticker
- $MNKD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 592
- Headquarters
- Danbury, United States
- Website
- mannkindcorp.com
MannKind Metrics
BasicAdvanced
$1.1B
-
-$0.16
1.10
-
Price and volume
Market cap
$1.1B
Beta
1.1
52-week high
$6.51
52-week low
$2.23
Average daily volume
3.4M
Financial strength
Current ratio
1.719
Quick ratio
1.287
Long term debt to equity
-6.269
Total debt to equity
-6.456
Interest coverage (TTM)
0.15%
Profitability
EBITDA (TTM)
19.535
Gross margin (TTM)
75.39%
Net profit margin (TTM)
-11.08%
Operating margin (TTM)
1.85%
Effective tax rate (TTM)
10.36%
Revenue per employee (TTM)
$660,000
Management effectiveness
Return on assets (TTM)
0.79%
Return on equity (TTM)
71.36%
Valuation
Price to revenue (TTM)
2.46
Price to book
-16.14
Price to tangible book (TTM)
-2.41
Price to free cash flow (TTM)
-53.397
Free cash flow yield (TTM)
-1.87%
Free cash flow per share (TTM)
-0.066
Growth
Revenue change (TTM)
30.45%
Earnings per share change (TTM)
-245.69%
3-year revenue growth (CAGR)
35.53%
3-year earnings per share growth (CAGR)
-4.94%
10-year earnings per share growth (CAGR)
-28.09%
What the Analysts think about MannKind
Analyst ratings (Buy, Hold, Sell) for MannKind stock.
Analyst projections of the future price of MannKind stock.
Bulls say / Bears say
May 29, 2026 (Reuters) – The U.S. FDA approved expanded use of Afrezza inhaled insulin for children aged 6 and older, broadening MannKind’s addressable market and leveraging its unique needle-free delivery in pediatric diabetes care (Reuters).
May 6, 2026 (Reuters) – MannKind entered a strategic collaboration with United Therapeutics to develop an inhalable ralinepag therapy for pulmonary arterial hypertension, receiving a $5 million upfront payment and eligible for up to $35 million in milestones plus 10 % royalties, diversifying its orphan lung disease pipeline (Reuters).
Aug 5, 2026 (Reuters) – MannKind reported Q2 2026 revenue of $109.4 million, up 43 % year-over-year and slightly above expectations, driven by growth in Afrezza’s pediatric launch and FUROSCIX sales, demonstrating strong commercial momentum (Reuters).
May 7, 2026 (Reuters) – MannKind’s Q1 revenue of $90.2 million fell short of analysts’ consensus estimate of $106.6 million, indicating challenges in sales execution (Reuters).
May 7, 2026 (Reuters) – Collaboration and services revenue declined in Q1 due to lower sales to United Therapeutics, reducing a key recurring revenue stream (Reuters).
Aug 5, 2026 (Reuters) – MannKind posted a net loss before tax of $19.138 million in Q2 2026 (EPS -$0.06), reversing a prior-year profit and underscoring margin pressure from product launch expenses (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2026.
MannKind Financial Performance
Revenues and expenses
MannKind Earnings Performance
Company profitability
Upcoming events
No upcoming events
MannKind News
AllArticlesVideos
Funds containing MannKind
AllUSDGBPEUR
Fund name | Fund size | $MNKD weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.08% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.08% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.04% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.